Guizhou Yibai Pharmaceutical Co., Ltd. (600594.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenCNY 3.56

From 52W high−19.17%

Volume18.30M

Market capCNY 3.21B

P/E (TTM)−9.7x

P/S (TTM)1.6x

Div yield—

Key dataSep 18, 2026

Open

CNY 3.56

From 52W high

−19.17%

Volume

18.30M

Market cap

CNY 3.21B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−25.2x

P/E (TTM)

−9.7x

RSI (14)

43.1

MomentumView details →

1D Return

+9.95%

YTD Return

−10.55%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

−9.7x

EV/EBITDA

−25.2x

EV/Sales

1.7x

P/S (TTM)

1.6x

P/B (TTM)

1.5x

ProfitabilityView details →

Gross Margin

59.15%

Net Margin

−20.33%

EBITDA Margin

−6.87%

ROE (TTM)

−16.20%

ROA (TTM)

−10.29%

Asset Turnover

0.50x

GrowthView details →

Revenue YoY

−18.19%

EPS YoY

−36.36%

FCF YoY

+414.44%

Revenue CAGR 3Y

−12.02%

EPS CAGR 3Y

−4.48%

EBITDA YoY

—

MomentumView details →

1D Return

+9.95%

YTD Return

−10.55%

1Y Return

−15.64%

RSI (14)

43.1

vs 50D SMA

−3.98%

vs 200D SMA

−8.45%

Capital & dividendView details →

Debt/Equity

0.27x

Current Ratio

1.70x

Quick Ratio

1.06x

Div Yield

—

Div Rate

—

Div Growth 1Y

−49.23%

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

1.72B

Net Income (TTM)

−349.70M

Op. CF (TTM)

294.36M

Latest newsMore news →

Yibai Pharmaceutical announced its first-half 2026 results: revenue of 689 million yuan, down 30.58% year-on-year, and net loss attributable to shareholders widened to 80.34 million yuan from 19.90 million yuan a year earlier.31d ago

Yibai Pharmaceutical received a Notice of Administrative Penalty from the Guizhou Provincial Drug Administration for failing to comply with Good Manufacturing Practice for drugs, and is proposed to be fined 700,000 yuan.51d ago

Similar companies

威尔药业603351.SH Regencell Bioscience Holdings LimitedRGC 康惠股份603139.SH CF PharmTech, Inc.02652.HK ST交昂600530.SH Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.01349.HK Find similar companies →

Latest newsMore news →

Yibai Pharmaceutical announced its first-half 2026 results: revenue of 689 million yuan, down 30.58% year-on-year, and net loss attributable to shareholders widened to 80.34 million yuan from 19.90 million yuan a year earlier.31d ago Yibai Pharmaceutical received a Notice of Administrative Penalty from the Guizhou Provincial Drug Administration for failing to comply with Good Manufacturing Practice for drugs, and is proposed to be fined 700,000 yuan.51d ago